Effect of pemetrexed combined with thalidomide on treatment of patients with advanced pulmonary adenocarcinoma

Sun J M, Park J O, Won Y W. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small celllung cancer Implications for selection of patients for maintenance therapy [J]. Journal of Thoracic Oncology, 2010(4):540.

Hanna N, Shepherd F A, Fossella F V. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J]. Journal of Clinical Oncology, 2004(9):1589.

Demarinis F, Paul S, Hanna N. Survival update for the phase Ⅲ study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC)[abstract] [J]. Journal of Clinical Oncology, 2006, (Suppl18):Abstract7133.

Moro-Sibilot D, Vergnenegre A, Smit E F. Second-line therapy for NSCLC in clinical practice:baseline results of the European SELECTTION observational study [J]. Current Medical Research and Opinion, 2010, (11):2661.

De Sanctis J B, Mijares M, Suárez A. Pharmacological properties of thalidomide and its analogues [J]. Recent Patents on Inflammation and Allergy Drug Discovery, 2010(2):144.

Miller A A, Case D, Atkins J N. Phase Ⅱ study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer [J]. Journal of Thoracic Oncology, 2006(8):832.

Seagliotti G, Hanna N, Fossella F. The differential effieacy of pemetrexed according to NSCLC histology:a review of two Phase Ⅲ studies [J]. Oncologist, 2009(3):253.

Yang C H, Simms L, Park K. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as firstline treatment in East Asian patients with advanced nonsmall cell lung cancer:results of an exploratory subgroup analysisof a phase Ⅲ trial [J]. Journal of Thoracic Oncology, 2010(5):688.

Sandler A, Gray R, Perry M C. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J]. New England Journal of Medicine, 2006, (24):2542.

Merchant J J, Kim K, Mehta M P. Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer [J]. Clinical Lung Cancer, 2000(1):48.